Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Natural killer (NK) cells are crucial innate immune cells targeting infected and malignant cells.
• NK cells utilize a balance of inhibitory and stimulatory receptors for target cell recognition and elimination.
• Pre-clinical studies demonstrate NK cell potential in adoptive transfer for cancer treatment.

Purpose of the Study:

• To review current NK cell therapy approaches for cancer immunotherapy.
• To discuss methods for NK cell preparation and ex-vivo expansion for allogeneic cell therapies.
• To explore vector delivery systems for engineering NK cells with chimeric antigen receptors (CARs).

Main Methods:

• Review of pre-clinical and clinical literature on NK cell therapy.
• Analysis of NK cell isolation and expansion techniques.
• Examination of CAR engineering strategies and vector systems for NK cells.

Main Results:

• NK cells exhibit potent anti-tumor effects, making them attractive for immunotherapy.
• Ex-vivo expansion enables the generation of "off-the-shelf" allogeneic NK cell doses.
• CAR-NK cell therapies are under investigation in clinical trials for various cancers.

Conclusions:

• NK cell therapy, particularly CAR-NK, represents a promising avenue for cancer immunotherapy.
• Standardized methods for NK cell preparation and expansion are essential for therapeutic efficacy.
• Advancements in vector delivery systems are key to successful CAR-NK cell engineering.